JTJason D. Turner

Jason D. Turner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jason D. Turner has a total of 336 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew Filer

    Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom; NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom

    9 shared publications
  • Christopher Dominic Buckley

    Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK

    9 shared publications
  • Andrew Filer

    Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), UK; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and NIHR Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Rheumatology Research Group, School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UK; Birmingham Tissue Analytics, Institute of Translational Medicine, University of Birmingham, Birmingham, UK

    7 shared publications
  • Adam P. Croft

    Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK

    6 shared publications
  • Amy Jane Naylor

    Department of Inflammation and Ageing School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham United Kingdom

    5 shared publications
  • Jennifer L. Marshall

    Institute of Inflammation and Ageing, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK

    5 shared publications

Latest Publications

  • Open Access

    Cellular heterogeneity in hypertrophic burn scars in response to carbon dioxide laser therapy

    by Yung-Yi Chen, Christopher Mahony, Jason Turner, Charlotte G. Smith, Abdulrazak Abdulsalam, Ezekwe Amirize, Amberley Prince, Adrian Heagerty, Claudia Roberts, Adam Croft, et al.

    Ablative fractional carbon dioxide (AFCO2) laser therapy is used for treating pathological scarring. However, mechanisms underlying reduction in hypertrophic scarring are poorly understood. We investigated cellular mechanisms of AFCO2 laser therapy by performing single-cell RNA sequencing (scRNA-seq) on skin biopsies from burn survivors with hypertrophic scars before and after three sessions of AFCO2 therapy. Scar reduction was assessed subjectively and objectively. Those with a good response (GR) to laser therapy have scars less than 6 years from injury, whereas poor responders (PR) have scars over 6 years since injury. ScRNA-seq analysis of skin biopsies reveals that genes enriched in GR are associated with extracellular matrix and structure organisation (COL14A1, POSTN, SPARC); whereas genes enriched in PR are related to enhanced immune inflammatory responses (CXCL14, JUN, TNC). Notably, expression of the pro-fibrotic gene Engrailed-1 (EN1) remains elevated in PR scars compared to GR. The ECM-regulatory gene TIMP-1 (Tissue Inhibitor of Metalloproteinases 1) is also significantly upregulated in PR scars following treatment relative to GR scars, although at the protein level TIMP1 levels decrease in PR but increase in GR after therapy. The regenerative-associated gene, TRPS1 (Transcriptional Repressor GATA Binding 1) expression demonstrates opposing regulation post treatment, with upregulation observed in GR scars but downregulation in PR scars, underscoring distinct transcriptional trajectories associated with differential therapeutic outcomes. Finally, distinct intercellular communication networks and differentiation trajectories are observed after AFCO2, with regenerative mesenchymal fibroblasts predominating in GR but inflammatory fibroblasts associated with PR. We conclude AFCO2 laser therapy is more effective if done early after injury and distinct fibroblast recruitment is associated with a good response, specifically regenerative fibroblasts.


  • Open Access

    Hormonal risk factors and androgen and glucocorticoid dysregulation in Sjogren’s disease and non-Sjogren’s sicca

    by Jason D Turner, Jessica Tsapparelli, Lorna C Gilligan, Valentina Pucino, Matilde Bandeira, Aliaksandra Baranskaya, Saaeha Rauz, Ana Poveda-Gallego, Jon Higham, Andrea Richards, et al.

    Objectives: The strong female sex bias in Sjögren’s disease (SjD) remains poorly understood. We evaluated hormonal risk factors and steroidal hormones in a well-characterized cohort. Methods: Newly presenting patients investigated for SjD at a multidisciplinary clinic completed a hormonal risk factor questionnaire. One hundred eighty-four females with a diagnosis of SjD or non-SjD Sicca were included. Steroids were extracted from 88 consecutively recruited SjD and 59 Sicca serum samples and analysed via liquid chromatography tandem mass spectrometry. Sex steroid, glucocorticoid and mineralocorticoid data were compared with those from 165 healthy controls. Results: A history of hirsutism was negatively associated with SjD even when corrected for smoking status, ethnicity, age and symptom duration (OR 0.14, 95% CI 0.04, 0.57; P = 0.006), whereas hysterectomy and ovary removal were positively associated, whether up to time of recruitment (hysterectomy OR 3.29, 95% CI 1.19, 9.11; P = 0.02) or to symptom onset (hysterectomy OR 5.8, 95% 1.52, 22.1; P = 0.01). Participants reporting hirsutism had higher androstenedione levels (2.51 vs 1.80 nmol/l; P = 0.03) and in pre-menopause, androstenedione and testosterone were higher in non-SjD sicca than both SjD and healthy controls. Within the whole cohort, androstenedione levels were inversely correlated with minor salivary gland focus score (r = −0.44; P = 0.03). Lower glucocorticoids were seen in both SjD and Sicca compared with healthy controls and negatively correlated with symptoms. Conclusion: Participants with SjD were less likely to report hirsutism and had lower androstenedione and testosterone pre-menopause when compared with non-SjD sicca. The role of androgens in modulating salivary gland inflammation should be further investigated.


  • Open Access

    Lactate signalling leads to aggregation of immune-inflammatory hotspots and SLC5A12 blockade promotes their resolution

    by Michelangelo Certo, Elena Pontarini, Sebastian G. Gilbert, Ronny Schmidt, Jason D. Turner, Davide Lucchesi, Daria Apostolo, Giulia Cavallaro, Charlotte G. Smith, Serena Colafrancesco, et al.

    Ectopic lymphoid structures (ELS) are aggregates of lymphoid cells that often form within inflamed tissues in patients with autoimmune diseases, cancer, infectious diseases and cardiovascular conditions. These structures drive B cell maturation into memory B cells and plasma cells through B cell and T cell co-stimulation, and their role in pathogenesis is increasingly recognized. Understanding how ELS develop and persist in inflamed tissues is essential for elucidating the pathogenesis and treatment responses in diseases in which they have a prominent role. Here we show that metabolic pathways and specific metabolites, in particular lactate, are master regulators of ELS organization in Sjögren’s disease (SjD), the second-most common autoimmune rheumatic disease. Furthermore, inhibiting lactate uptake by lactate transporters, specifically by SLC5A12 blockade, represents a previously unappreciated checkpoint in autoimmune inflammatory diseases. This approach results in multidimensional pro-resolution effects, including reduced inflammatory cytokine levels, enhanced T cell egress from inflamed sites and diminished T cell and B cell areas and their segregation within ELS.


  • Open Access

    CD4+ tissue-resident memory Th17 cells are a major source of IL-17A in Spondyloarthritis synovial tissue

    by Feng Liu, Hui Shi, Jason D. Turner, Rachel Anscombe, Jiaqi Li, Takuya Sekine, Ariane Hammitzsch, Devika Agarwal, Christopher Mahony, Jiewei Chen, et al.


  • Open Access

    Cellular heterogeneity in hypertrophic burn scars in response to carbon dioxide laser therapy

    by Janet Lord, Yung-Yi Chen, Christopher Mahony, Jason Turner, Charlotte Smith, Abdulrazak Abdulsalam, Ezekwe Amirize, Amberley Prince, Adrian Heagerty, Claudia Roberts, et al.

    Ablative fractional carbon dioxide (AFCO2) laser therapy is widely used for treating pathological scarring, with promising clinical results. However, mechanisms underlying reduction hypertrophic scarring are poorly understood. We investigated the cellular mechanisms of AFCO2 laser therapy by performing single-cell RNA sequencing (scRNA-seq) on skin biopsies from burn survivors with hypertrophic scars before and after AFCO2 therapy. Those with a good response (GR) to laser therapy, assessed objectively and subjectively, generally had scars less than 6 years from injury, whereas poor responders (PR) had more mature scars over 6 years since injury. Additionally, scRNA-seq analysis revealed that genes enriched in GR were associated with extracellular matrix and structure organisation (COL14A1, POSTN, SPARC); whereas genes enriched in PR were related to enhanced immune inflammatory responses (CXCL14, JUN, TNC). Distinct intercellular communication networks and differentiation trajectories were observed after AFCO2, with regenerative mesenchymal fibroblasts predominating in GR but inflammatory fibroblasts associated with PR.

  • Top Cited Papers
    Open Access

    Molecular and spatial analysis of tertiary lymphoid structures in Sjogren’s syndrome

    by Saba Nayar, Jason D. Turner, Saba Asam, Eanna Fennell, Matthew Pugh, Serena Colafrancesco, Onorina Berardicurti, Charlotte G. Smith, Joe Flint, Ana Teodosio, et al.

    Tertiary lymphoid structures play important roles in autoimmune and non-autoimmune conditions. While many of the molecular mechanisms involved in tertiary lymphoid structure formation have been identified, the cellular sources and temporal and spatial relationship remain unknown. Here we use combine single-cell RNA-sequencing, spatial transcriptomics and proteomics of minor salivary glands of patients with Sjogren’s disease and Sicca Syndrome, with ex-vivo functional studies to construct a cellular and spatial map of key components involved in the formation and function of tertiary lymphoid structures. We confirm the presence of a fibroblast cell state and identify a pericyte/mural cell state with potential immunological functions. The identification of cellular properties associated with these structures and the molecular and functional interactions identified by this analysis may provide key therapeutic cues for tertiary lymphoid structures associated conditions in autoimmunity and cancer.


  • Top Cited Papers
    Open Access

    A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease

    by Tom Thomas, Matthias Friedrich, Charlotte Rich-Griffin, Mathilde Pohin, Devika Agarwal, Julia Pakpoor, Carl Lee, Ruchi Tandon, Aniko Rendek, Dominik Aschenbrenner, et al.

    Precision medicine in immune-mediated inflammatory diseases (IMIDs) requires a cellular understanding of treatment response. We describe a therapeutic atlas for Crohn’s disease (CD) and ulcerative colitis (UC) following adalimumab, an anti-tumour necrosis factor (anti-TNF) treatment. We generated ~1 million single-cell transcriptomes, organised into 109 cell states, from 216 gut biopsies (41 subjects), revealing disease-specific differences. A systems biology-spatial analysis identified granuloma signatures in CD and interferon (IFN)-response signatures localising to T cell aggregates and epithelial damage in CD and UC. Pretreatment differences in epithelial and myeloid compartments were associated with remission outcomes in both diseases. Longitudinal comparisons demonstrated disease progression in nonremission: myeloid and T cell perturbations in CD and increased multi-cellular IFN signalling in UC. IFN signalling was also observed in rheumatoid arthritis (RA) synovium with a lymphoid pathotype. Our therapeutic atlas represents the largest cellular census of perturbation with the most common biologic treatment, anti-TNF, across multiple inflammatory diseases.


  • Open Access

    CD4+ tissue-resident memory Th17 cells are a major source of IL-17A in Spondyloarthritis synovial tissue

    by Feng Liu, Hui Shi, Jason D Turner, Rachel Anscombe, Jiaqi Li, Takuya Sekine, Ariane Hammitzsch, Devika Agarwal, Christopher Mahony, Jiewei Chen, et al.

    Objectives: Interleukin (IL)-17A is a key driver of Spondyloarthritis (SpA) joint pathology. We aimed to identify its cellular source in synovial tissue from patients with two forms of SpA namely Axial SpA (AxSpA) and Psoriatic arthritis (PsA). Methods: Synovial tissue from patients with SpA was profiled using single-cell RNA sequencing (scRNA-seq: AxSpA, n=5 and PsA, n=6) or spatial RNA profiling (PsA, n=4). CellPhoneDB was used to infer cell–cell communication. Tissue resident memory Th17 (TRM17)-like cells were generated in vitro using blood memory CD4+ T cells from SpA patients. An epigenetic inhibitor library, siRNA and clustered regularly interspaced short palindromic repeats (CRISPR) were used to identify epigenetic regulator(s) for TRM17. Results: scRNA-seq showed that CD4+CXCR6+ TRM17 cells are the predominant spontaneous IL17A producers in SpA synovium. Cell-cell communication and single-cell spatial analysis support the interaction between TRM17 and CLEC10A+ dendritic cells, which were activated in SpA. Both sublining and lining fibroblasts in SpA synovium showed evidence of IL-17A activation. In vitro-generated CD4+ TRM17-like cells phenocopied joint tissue TRM17, producing IL-17A/F upon T cell receptor (TCR) stimulation, which was further enhanced by cytokines. Perturbation of BRD1 inhibited the generation of TRM17-like cells. Conclusions: CD4+ TRM17 cells are the predominant source of IL-17A in SpA synovial tissue. TCR stimulation is essential for the secretion of IL-17A by CD4+TRM17-like cells. The epigenetic regulator BRD1 contributes to the generation of CD4+TRM17. Depleting CD4+TRM17 cells in SpA is thus a therapeutic strategy with potential to induce long-term remission. Key messages: What is already known on this topic: Interleukin (IL)-17A plays a key role in the immunopathogenesis of Spondyloarthritis (SpA), but its cellular source in joint tissue has not been determined previously. The induction and accumulation of CD4+ tissue resident memory Th17 (TRM17) cells following the clearance of pathogens has been described in skin, lung and kidney. Whether CD4+ TRM17 cells also accumulate in the joint and contribute to the pathology of SpA is not clear. What this study adds: CD4+ TRM17 cells are present in SpA synovial tissue and are the predominant source of IL17A CD4+ TRM17 cells in SpA joints express IL17A without any in vitro exogenous stimulation T cell receptor (TCR) rather than cytokine stimulation is essential for IL-17A production by CD4+ TRM17-like cells The epigenetic regulator BRD1 contributes to the generation of CD4+ TRM17-like cells. How this study might affect research, practice or policy: Our findings identify CD4+ TRM17 cells as the primary source of IL-17A in SpA synovium, a previously unrecognized role for these cells. Key questions remain: How do CD4+ TRM17 cells relate to IL-17A producers in synovial fluid? What mechanisms induce and maintain them in the joint? How do they interact with other cells to promote arthritis? These questions warrant further investigation. In addition, our data suggest that targeting CD4+ TRM17 cells, the “factory” of IL-17A in SpA synovial tissue, has the potential to induce long-term remission, encouraging future efforts to develop new therapies to deplete CD4+ TRM17 cells in SpA.

  • Open Access

    Type-H endothelial cell protein Clec14a orchestrates osteoblast activity during trabecular bone formation and patterning

    by Georgiana Neag, Jonathan Lewis, Jason D. Turner, Julia E. Manning, Isaac Dean, Melissa Finlay, Gowsihan Poologasundarampillai, Jonathan Woods, Muhammad Arham Sahu, Kabir A. Khan, et al.

    Type-H capillary endothelial cells control bone formation during embryogenesis and postnatal growth but few signalling mechanisms underpinning this influence have been characterised. Here, we identify a highly expressed type-H endothelial cell protein, Clec14a, and explore its role in coordinating osteoblast activity. Expression of Clec14a and its ligand, Mmrn2 are high in murine type-H endothelial cells but absent from osteoblasts. Clec14a−/− mice have premature condensation of the type-H vasculature and expanded distribution of osteoblasts and bone matrix, increased long-bone length and bone density indicative of accelerated skeletal development, and enhanced osteoblast maturation. Antibody-mediated blockade of the Clec14a-Mmrn2 interaction recapitulates the Clec14a−/− phenotype. Endothelial cell expression of Clec14a regulates osteoblast maturation and mineralisation activity during postnatal bone development in mice. This finding underscores the importance of type-H capillary control of osteoblast activity in bone formation and identifies a novel mechanism that mediates this vital cellular crosstalk.


  • Top Cited Papers

    The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts

    by Jasna Friščić, Martin Böttcher, Christiane Reinwald, Heiko Bruns, Benjamin Wirth, Samantha-Josefine Popp, Kellie Irene Walker, Jochen A. Ackermann, Xi Chen, Jason Turner, et al.